Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02975934 · ClinicalTrials.gov registry record · Phase 3
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
A Phase 3 study, sponsored by pharmaand.
- Completed
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
NCT02975934 is a Phase 3 study that has completed, run by pharmaand. The registered enrollment target is 405 participants.
The verdict
NCT02975934, a Phase 3 study, has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
Interventions
- DRUG Rucaparib
- DRUG Abiraterone acetate or Enzalutamide or Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2017-06-13 |
| Est. Completion | 2024-08-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02975934
The ClinicalTrials.gov registry entry for NCT02975934 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rucaparib is the first listed.
NCT02975934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02975934 about?
NCT02975934 is a clinical study titled "A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency". The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel...
What is the current status of trial NCT02975934?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2017-06-13. Estimated completion is 2024-08-08.
What interventions are being tested in trial NCT02975934?
The interventions under investigation include: Rucaparib (DRUG), Abiraterone acetate or Enzalutamide or Docetaxel (DRUG).
Who is sponsoring clinical trial NCT02975934?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.